KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12

Arun Srivastava, H. Boswell, Nyla A. Heerema, Piruz Nahreini, Richard C. Lauer, Asok Antony, Ronald Hoffman, Guido J. Tricot

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The factors that initiate and maintain the abnormal hematopoietic clone in the myelodysplastic syndromes (MDS) remain largely unknown. We describe a patient with MDS associated with an abnormal karyotype, 46,XY,t(5;12)(q31;p12). According to the FAB cooperative group classification, the patient was classified as chronic myelomonocytic leukemia. Because of the particular chromosomal translocation, the structure-function relationship of three genes relevant to the translocation breakpoints, CSF2, FMS, and KRAS2, was studied in bone marrow and peripheral blood lymphocytes in this patient. No major structural alterations were observed at these three genetic loci. Although the levels of expression of the CSF2 and FMS genes remained unaltered, the KRAS2 oncogene was overexpressed approximately six-fold in bone marrow cells from the MDS patient compared with normal donors. We postulate that the RAS oncogene activation may be instrumental in the genesis of MDS.

Original languageEnglish
Pages (from-to)61-71
Number of pages11
JournalCancer Genetics and Cytogenetics
Volume35
Issue number1
DOIs
StatePublished - Oct 1 1988

Fingerprint

Myelodysplastic Syndromes
Oncogenes
Leukemia, Myelomonocytic, Chronic
Abnormal Karyotype
Genetic Translocation
Genetic Loci
Bone Marrow Cells
Genes
Clone Cells
Bone Marrow
Tissue Donors
Lymphocytes

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. / Srivastava, Arun; Boswell, H.; Heerema, Nyla A.; Nahreini, Piruz; Lauer, Richard C.; Antony, Asok; Hoffman, Ronald; Tricot, Guido J.

In: Cancer Genetics and Cytogenetics, Vol. 35, No. 1, 01.10.1988, p. 61-71.

Research output: Contribution to journalArticle

Srivastava, Arun ; Boswell, H. ; Heerema, Nyla A. ; Nahreini, Piruz ; Lauer, Richard C. ; Antony, Asok ; Hoffman, Ronald ; Tricot, Guido J. / KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. In: Cancer Genetics and Cytogenetics. 1988 ; Vol. 35, No. 1. pp. 61-71.
@article{5468672e99ed48a09a8d0237bef81eec,
title = "KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12",
abstract = "The factors that initiate and maintain the abnormal hematopoietic clone in the myelodysplastic syndromes (MDS) remain largely unknown. We describe a patient with MDS associated with an abnormal karyotype, 46,XY,t(5;12)(q31;p12). According to the FAB cooperative group classification, the patient was classified as chronic myelomonocytic leukemia. Because of the particular chromosomal translocation, the structure-function relationship of three genes relevant to the translocation breakpoints, CSF2, FMS, and KRAS2, was studied in bone marrow and peripheral blood lymphocytes in this patient. No major structural alterations were observed at these three genetic loci. Although the levels of expression of the CSF2 and FMS genes remained unaltered, the KRAS2 oncogene was overexpressed approximately six-fold in bone marrow cells from the MDS patient compared with normal donors. We postulate that the RAS oncogene activation may be instrumental in the genesis of MDS.",
author = "Arun Srivastava and H. Boswell and Heerema, {Nyla A.} and Piruz Nahreini and Lauer, {Richard C.} and Asok Antony and Ronald Hoffman and Tricot, {Guido J.}",
year = "1988",
month = "10",
day = "1",
doi = "10.1016/0165-4608(88)90123-9",
language = "English",
volume = "35",
pages = "61--71",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12

AU - Srivastava, Arun

AU - Boswell, H.

AU - Heerema, Nyla A.

AU - Nahreini, Piruz

AU - Lauer, Richard C.

AU - Antony, Asok

AU - Hoffman, Ronald

AU - Tricot, Guido J.

PY - 1988/10/1

Y1 - 1988/10/1

N2 - The factors that initiate and maintain the abnormal hematopoietic clone in the myelodysplastic syndromes (MDS) remain largely unknown. We describe a patient with MDS associated with an abnormal karyotype, 46,XY,t(5;12)(q31;p12). According to the FAB cooperative group classification, the patient was classified as chronic myelomonocytic leukemia. Because of the particular chromosomal translocation, the structure-function relationship of three genes relevant to the translocation breakpoints, CSF2, FMS, and KRAS2, was studied in bone marrow and peripheral blood lymphocytes in this patient. No major structural alterations were observed at these three genetic loci. Although the levels of expression of the CSF2 and FMS genes remained unaltered, the KRAS2 oncogene was overexpressed approximately six-fold in bone marrow cells from the MDS patient compared with normal donors. We postulate that the RAS oncogene activation may be instrumental in the genesis of MDS.

AB - The factors that initiate and maintain the abnormal hematopoietic clone in the myelodysplastic syndromes (MDS) remain largely unknown. We describe a patient with MDS associated with an abnormal karyotype, 46,XY,t(5;12)(q31;p12). According to the FAB cooperative group classification, the patient was classified as chronic myelomonocytic leukemia. Because of the particular chromosomal translocation, the structure-function relationship of three genes relevant to the translocation breakpoints, CSF2, FMS, and KRAS2, was studied in bone marrow and peripheral blood lymphocytes in this patient. No major structural alterations were observed at these three genetic loci. Although the levels of expression of the CSF2 and FMS genes remained unaltered, the KRAS2 oncogene was overexpressed approximately six-fold in bone marrow cells from the MDS patient compared with normal donors. We postulate that the RAS oncogene activation may be instrumental in the genesis of MDS.

UR - http://www.scopus.com/inward/record.url?scp=0023804346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023804346&partnerID=8YFLogxK

U2 - 10.1016/0165-4608(88)90123-9

DO - 10.1016/0165-4608(88)90123-9

M3 - Article

C2 - 3180012

AN - SCOPUS:0023804346

VL - 35

SP - 61

EP - 71

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -